Find uplifting stories about heroes, innovations, and solutions
413 results for "kras mutations"
A breakthrough drug targeting previously "undruggable" KRAS mutations has approximately doubled survival time for metastatic pancreatic cancer patients compared to chemotherapy. The development marks a historic shift for a disease that affects over 90% of pancreatic cancer cases. --- ##
A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers. After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.
A pit bull named Theodore has a rare genetic mutation that gives him a fluffy, teddy bear coat on a classic pit bull face. After being rehomed six times, he finally found his perfect match with Joanna Meadows.
Dutch researchers tested every possible mutation in a little-known breast cancer gene, creating a library that tells doctors exactly which patients face real risk. The discovery ends years of uncertainty for women carrying PALB2 mutations.
After decades of slow progress, breakthrough drugs targeting a genetic mutation found in 90% of pancreatic cancers are nearing FDA approval in 2026. The KRAS inhibitors now in late-stage trials could transform treatment for one of medicine's deadliest diseases.
Scientists just proved that two harmful genetic mutations can actually restore normal function when combined, confirming a 60-year-old hypothesis. This breakthrough could transform how doctors diagnose and treat thousands of rare genetic diseases.
A breakthrough drug called daraxonrasib is giving hope to pancreatic cancer patients after scientists spent nearly 50 years trying to target the KRAS mutation. Patients like 36-year-old Leanna Stokes are living far longer than expected thanks to this medical breakthrough.
Researchers screened 774 FDA-approved drugs using zebrafish to create a precision medicine map for autism, identifying levocarnitine as a compound that reverses brain deficits caused by specific genetic mutations. The breakthrough could help doctors match treatments to individual patients based on their unique genetic profile.
Researchers created the first complete map of how hundreds of mutations in a key cancer gene affect tumor growth. The breakthrough could help doctors predict cancer behavior and personalize treatments for patients.
Scientists discovered how hidden blood mutations worsen inflammatory bowel disease in millions of Americans. Even better, they found an existing safe drug that reverses the damage.
Scientists created a system that reveals how hundreds of different cancer mutations funnel into the same control points, opening the door to treatments that work across many genetic causes. The breakthrough could transform how doctors tackle diseases driven by complex genetic changes.
For the first time in years, doctors have a promising new weapon against one of the deadliest cancers. A targeted therapy that blocks specific gene mutations is bringing fresh hope to pancreatic cancer patients and their families.
%2Fhttps%3A%2F%2Ftf-cmsv2-smithsonianmag-media.s3.amazonaws.com%2Ffiler_public%2F3d%2F01%2F3d01b02f-4e5e-4d94-a911-23a06aee8783%2Fgettyimages-2239147250.jpg)
Scientists discovered that a genetic mutation helping yaks survive at extreme altitudes could lead to treatments for multiple sclerosis and cerebral palsy. The breakthrough reveals how nature's adaptations might repair damaged nerve cells in people.
Scientists studying long-lived families discovered a rare genetic mutation that appears to tame inflammation while still fighting infections, potentially unlocking years of extra healthy living. The breakthrough could reveal why some families stay disease-free well into old age.
A breakthrough medication targeting a previously "undruggable" genetic mutation could transform treatment for one of the deadliest cancers. Patients in late-stage trials lived nearly twice as long when taking the new drug alongside chemotherapy.
Scientists have finally cracked a genetic mutation once thought impossible to treat, potentially transforming outcomes for 90% of pancreatic cancer patients. A new drug targeting KRAS mutations has doubled survival time compared to traditional chemotherapy.
An experimental once-daily pill nearly doubled survival time for patients with advanced pancreatic cancer, offering hope for one of the deadliest forms of the disease. The breakthrough targets a mutation present in over 90% of pancreatic tumors that scientists have struggled to treat for four decades.
A breakthrough drug from Revolution Medicines is giving real hope to pancreatic cancer patients for the first time in decades. The pill, called daraxonrasib, successfully targeted KRAS, a protein scientists once thought was impossible to drug.
A breakthrough drug called daraxonrasib targets the "undruggable" mutation behind 90% of pancreatic cancers, nearly doubling survival time in a major clinical trial. Patients lived 13.2 months compared to 6.7 months with standard chemotherapy.
Scientists at Florida A&M University discovered an experimental compound that makes deadly pancreatic cancer cells essentially kill themselves. The treatment blocked over 90% of cancer cell movement, offering new hope for one of the most lethal cancers.
Showing 20 of 413